References
  1. Monagle, P, et al. Antithrombotic therapy in children. CHEST . 2001;11:344S-370S.
  2. Centers for Disease Control and Prevention. Trends in Venous Thromboembolism-Related Pediatric Hospitalizations, 1994-2009. https://www.cdc.gov/ncbddd/dvt/features/pediatricgenetics-keyfindings-vte.html Accessed August 2, 2019.
  3. Boulet SL, Amendah D, Grosse SD, Hooper WC. Health care expenditures associated with venous thromboembolism among children. Thromb Res . 2012 May;129(5):583-7. Epub 2011 Aug 26.
  4. Fernandez MM, Hogue S, Preblick R, Kwong WJ. Review of the cost of venous thromboembolism. Clinicoecon Outcomes Res . 2015;7:451–462. Published 2015 Aug 28.
  5. Kufel WD, Seabury RW, Darko W, Probst LA, Miller CD. Clinical Feasibility of Monitoring Enoxaparin Anti-Xa Concentrations: Are We Getting It Right?. Hosp Pharm . 2017;52(3):214–220.
  6. Stutsky, M. E., Reardon, D. P., & Lee, A. I. (2015). Clinical Practice Patterns of Anti-Xa Monitoring During Low Molecular Weight Heparin Therapy. Blood, 126(23), 3275. Accessed August 02, 2019. Retrieved from http://www.bloodjournal.org/content/126/23/3275.
  7. Garcia, DA, et al. Parental anticoagulants. CHEST . 2016;141:e245-e435.
  8. Leung M, Ho SH, Hamilton DP, et al. Utility of anti-xa monitoring in children receiving enoxaparin for therapeutic anticoagulation. J Pediatr Pharmacol Ther. 2005;10(1):43–50.
  9. Rosenbloom D, Ginsberg JS. Arguments against monitoring levels of anti-factor Xa in conjunction with low-molecularweight heparin therapy. Can J Hosp Pharm 2002;55:15-9.
  10. Bounameaux, H., De Moerloose, P. Is laboratory monitoring of low-molecular-weight heparin therapy necessary? No. Journal of Thrombosis and Haemostasis . 2004;2:551-4
  11. Enoxaparin. Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc . Riverwoods, IL. Available at: http://online.lexi.com. Accessed August 3, 2019.
  12. Dinh CN, Moffett BS, Galati M, Lee-Kim Y, Yee DL, Mahoney D. A Critical Evaluation of Enoxaparin Dose Adjustment Guidelines in Children. J Pediatr Pharmacol Ther. 2019;24(2):128–133.
  13. Paul A. Harris, Robert Taylor, Robert Thielke, Jonathon Payne, Nathaniel Gonzalez, Jose G. Conde, Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support, J Biomed Inform. 2009 Apr;42(2):377-81.
  14. IBM Corp. Released 2010. IBM SPSS Statistics for Windows, Version 19.0. Armonk, NY: IBM Corp.
  15. Khwaja A. KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract . 2012;120(4):c179-c184.
  16. van Ommen CH, Heijboer H, Büller HR, et al. Venous thromboembolism in childhood: a prospective two-year registry in The Netherlands. J Pediatr . 2001;139(5):676-681.
  17. Tuckuviene R, Christensen AL, Helgestad J, et al. Pediatric venous and arterial noncerebral thromboembolism in Denmark: a nationwide population-based study. J Pediatr . 2011;159(4):663-669.
  18. Takemoto CM, Sohi S, Desai K, et al. Hospital-associated venous thromboembolism in children: incidence and clinical characteristics. J Pediatr . 2014;164(2):332-338.
  19. Lee YR, Vega JA, Duong HN, et al. Monitoring Enoxaparin with Antifactor Xa Levels in Obese Patients. Pharmacotherapy . 2015;35(11):1007-1015.
  20. Ahuja T, Mousavi KM, Klejmont L, et al. Enoxaparin Dosing and AntiXa Monitoring in Specialty Populations: A Case Series of Renal-Impaired, Extremes of Body Weight, Pregnant, and Pediatric Patients. P T . 2018;43(10):609-614.